Home
About
Overview
Management Team
Board of Directors
Medical Advisory Board
Product Pipeline
Overview
APX3330
APX2009 and APX2014
Phentolamine Ophthalmic Solution 0.75%
Scientific Posters and Publications
Partnerships
Clinical Trials
Overview
VEGA-2 Pivotal Phase 3 Trial of Phentolamine Ophthalmic Solution 0.75% in Presbyopia
Completed
ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330
Completed
MIRA-4: Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects
Completed
MIRA-3
Completed
MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol
Completed
LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol
Completed
VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine
Completed
News & Media
Press Releases
Presentations
Events
Ocuphire in the News
Investors
Overview
News / Events
Company Information
Financial Information
Stock Data
SEC Filings
Corporate Governance
Contact
Careers
Presentations
News & Media
News & Media
Press Releases
Presentations
Events
Ocuphire in the News
Corporate Presentation
Investor Conference Call and Webcast Audio Recording
Spotlight on Oral Therapies for Retina | George Magrath, MD, CEO
OIS Retina 2023 Innovation Showcase - Ronil Patel, MS, SVP, Operations & Business Development
Ocuphire ZETA-1 Topline Results Conference Call Presentation
OIS XII, Retina Innovation Showcase
Ocuphire APX3330 KOL Event October 2022
OIS Retina 2022 - Mina Sooch
Eyecelerator@ASCRS 2022
MIRA-3 Topline Results Conference Call Presentation
1
2
Next »
